News Website

Venous Thromboembolism Risk Associated With Relugolix-estradiol-norethisterone Acetate Combination Therapy.

Relugolix, an oral GnRH receptor antagonist, is effective in treating uterine myomas and endometriosis. However, concerns persist regarding the venous thromboembolism (VTE) risk associated with its combination with oral estradiol …

Published: Nov. 22, 2025, midnight

Read Full Article

add-back therapy endometriosis hemostasis relugolix uterine fibroid

This 23-year-old wouldn't wish her chronic pain on her 'worst enemy' - The Courier | Ballarat, VIC

This 23-year-old wouldn't wish her chronic pain on her 'worst enemy' The Courier | Ballarat, VIC

Published: Nov. 21, 2025, 8:02 p.m.

Read Full Article

Op-ed: Building better standards in women's health through measurement - Fierce Healthcare

Op-ed: Building better standards in women's health through measurement Fierce Healthcare

Published: Nov. 21, 2025, 3:30 p.m.

Read Full Article

President Trump says Democrats’ video message to military is ‘seditious behavior’ punishable by death - Cleveland.com

President Trump says Democrats’ video message to military is ‘seditious behavior’ punishable by death Cleveland.com

Published: Nov. 21, 2025, 2:40 p.m.

Read Full Article

National Women’s Soccer League launches CPR initiative - FemTech World

National Women’s Soccer League launches CPR initiative FemTech World

Published: Nov. 21, 2025, 2:03 p.m.

Read Full Article

Tracy Clifford Opens Up About Important Untalked Topic Despite Her Usual Privacy Online - Emegypt

Tracy Clifford Opens Up About Important Untalked Topic Despite Her Usual Privacy Online Emegypt

Published: Nov. 21, 2025, 12:33 p.m.

Read Full Article

Understanding Endometriosis: Realities and Essential Support Systems - newshub.co.uk

Understanding Endometriosis: Realities and Essential Support Systems newshub.co.uk

Published: Nov. 21, 2025, 10:09 a.m.

Read Full Article

Research explores nervous system pathways that heighten endometriosis pain - FemTech World

Research explores nervous system pathways that heighten endometriosis pain FemTech World

Published: Nov. 21, 2025, 9:02 a.m.

Read Full Article

Long-Term Burden of Adolescent-Onset Endometriosis: A Case Report Highlighting Recurrent Disease and Fertility-Preserving Dilemmas - Cureus

Long-Term Burden of Adolescent-Onset Endometriosis: A Case Report Highlighting Recurrent Disease and Fertility-Preserving Dilemmas Cureus

Published: Nov. 21, 2025, 6:43 a.m.

Read Full Article

🚨🇳🇿 NEW ZEALAND BANS PUBERTY BLOCKERS FOR TRANSGENDER MINORS New Zealand health officials announced doctors will stop prescribing puberty blockers to transgender minors starting December 19th, citing lack of "high-quality evidence" for - x.com

🚨🇳🇿 NEW ZEALAND BANS PUBERTY BLOCKERS FOR TRANSGENDER MINORS New Zealand health officials announced doctors will stop prescribing puberty blockers to transgender minors starting December 19th, citing lack of "high-quality …

Published: Nov. 21, 2025, 5:06 a.m.

Read Full Article

Latest Articles

Venous Thromboembolism Risk Associated With Relugolix-estradiol-norethisterone Acetate Combination Therapy.

This 23-year-old wouldn't wish her chronic pain on her 'worst enemy' - The Courier | Ballarat, VIC

Op-ed: Building better standards in women's health through measurement - Fierce Healthcare

President Trump says Democrats’ video message to military is ‘seditious behavior’ punishable by death - Cleveland.com

National Women’s Soccer League launches CPR initiative - FemTech World

Tracy Clifford Opens Up About Important Untalked Topic Despite Her Usual Privacy Online - Emegypt

Understanding Endometriosis: Realities and Essential Support Systems - newshub.co.uk

Research explores nervous system pathways that heighten endometriosis pain - FemTech World

Long-Term Burden of Adolescent-Onset Endometriosis: A Case Report Highlighting Recurrent Disease and Fertility-Preserving Dilemmas - Cureus

🚨🇳🇿 NEW ZEALAND BANS PUBERTY BLOCKERS FOR TRANSGENDER MINORS New Zealand health officials announced doctors will stop prescribing puberty blockers to transgender minors starting December 19th, citing lack of "high-quality evidence" for - x.com

Subscribe to Our Newsletter